Five markers useful for the distinction of canine mammary malignancy

• Published in: BMC veterinary research 2013-07, Vol.9 (1), p.138-138, Article 138
• Main Authors: Pawłowski, Karol M, Maciejewski, Henryk, Majchrzak, Kinga, Dolka, Izabella, Mol, Jan A, Motyl, Tomasz, Król, Magdalena
• Format: Article
• Language: English
• Subjects: Animal diseases; Animals; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Breast cancer; Cancer; carcinoma; Classification; Development and progression; Diagnosis; Diseases; Dog Diseases - diagnosis; Dog Diseases - genetics; Dog Diseases - metabolism; Dogs; Female; Gene expression; Gene Expression Regulation, Neoplastic; genes; Immunohistochemistry; Kruppel-Like Transcription Factors - metabolism; Life sciences; mammary neoplasms (animal); Mammary Neoplasms, Animal - diagnosis; Mammary Neoplasms, Animal - genetics; Mammary Neoplasms, Animal - metabolism; Membrane Proteins - metabolism; messenger RNA; Metalloendopeptidases - metabolism; Proteins; Real-Time Polymerase Chain Reaction; relaxin; Relaxin - metabolism; RNA; Rodents; Statistical analysis; Studies; Transcriptome; trees; Tumors; Veterinary medicine
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/1746-6148-9-138

BACKGROUND: Spontaneous canine mammary tumors constitute a serious clinical problem. There are significant differences in survival between cases with different tumor grades. Unfortunately, the distinction between various grades is not clear. A major problem in evaluating canine mammary cancer is identifying those, that are “truly” malignant. That is why the aim of our study was to find the new markers of canine malignancy, which could help to diagnose the most malignant tumors. RESULTS: Analysis of gene expression profiles of canine mammary carcinoma of various grade of malignancy followed by the boosted tree analysis distinguished a `gene set`. The expression of this gene set (sehrl, zfp37, mipep, relaxin, and magi3) differs significantly in the most malignant tumors at mRNA level as well as at protein level. Despite this `gene set` is very interesting as an additional tool to estimate canine mammary malignancy, it should be validated using higher number of samples. CONCLUSIONS: The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and therapy. So far, only two of them were linked with the cancer development.